Coeptis Therapeutics Holdings, Inc. (COEP) Stock Price, Financials & Summary

Price chart

Jun 30Jul 6Jul 9Jul 14Jul 17Jul 22Jul 27Jul 30

Key dataJul 30, 2026

Open$5.26

From 52W high−41.54%

Volume297453.00

Market cap$52.15M

P/E (TTM)—

P/S (TTM)36.9x

Div yield—

Key dataJul 30, 2026

Open

$5.26

From 52W high

−41.54%

Volume

297453.00

Market cap

$52.15M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.4x

P/E (TTM)

—

RSI (14)

37.7

MomentumView details →

1D Return

−8.57%

YTD Return

−63.37%

SummaryUpdated Mar 1, 2026

Coeptis Therapeutics, Inc. (NASDAQ:COEP) is a biopharmaceutical company founded in 2017 and headquartered in Wexford, Pennsylvania. The company went public in December 2020 and focuses on developing innovative cell therapy platforms and pharmaceutical products for cancer treatment. Coeptis operates in the highly specialized field of immuno-oncology, developing treatments that harness the body's immune system to fight cancer. The company is currently in the clinical development stage with no approved products generating significant revenue, making it a typical early-stage biotech investment with high risk and potential reward characteristics.

Ask drillr about Coeptis Therapeutics Holdings, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.4x

EV/Sales

33.7x

P/S (TTM)

36.9x

P/B (TTM)

2.5x

ProfitabilityView details →

Gross Margin

87.23%

Net Margin

−839.69%

EBITDA Margin

−769.03%

ROE (TTM)

−57.00%

ROA (TTM)

−60.00%

Asset Turnover

0.07x

GrowthView details →

Revenue YoY

+2148.85%

EPS YoY

—

FCF YoY

−12.41%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+50.27%

EBITDA YoY

−9.44%

MomentumView details →

1D Return

−8.57%

YTD Return

−63.37%

1Y Return

−50.75%

RSI (14)

37.7

vs 50D SMA

−44.19%

vs 200D SMA

−59.58%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

3.25x

Quick Ratio

3.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.11

EPS Surprise

—

Beats (12Q)

2/12

Next Q EPS Est

—

Avg Surprise (4Q)

4.48%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.41M

Net Income (TTM)

−11.87M

Op. CF (TTM)

−8.00M

Latest newsMore news →

Z Squared Inc. acquired 100% of the membership interests of Paradox Data, LLC from Paradox Infrastructure LLC for up to $25 million in Series A Convertible Preferred Stock.6d ago

Similar companies

ImageneBio IncIMA Kezar Life Sciences, Inc.KZR Tevogen Bio Holdings Inc.TVGN Elicio Therapeutics, Inc.ELTX Mereo BioPharma Group plcMREO Dogwood Therapeutics, Inc.DWTX Find similar companies →

Latest newsMore news →

Paradox Data LLC leased its building and approximately three-acre parcel in El Dorado, Arkansas to Paradox Infrastructure LLC for continued bitcoin mining operations at $1.00 per year base rent, with Z Squared Inc. liable for a one-time $500,000 relocation payment.6d ago Z Squared Inc. acquired 100% of the membership interests of Paradox Data, LLC from Paradox Infrastructure LLC for up to $25 million in Series A Convertible Preferred Stock.6d ago